The microarray test with spotted whole antigen of F. tularensis was used for the final evaluation, because pilot experiments showed that spotted LPS lead to many false negative results.
On the basis of an estimated 25% antigen prevalence (CI 95%), PCR and DNA microarray testing, together with sequencing revealed the presence of chlamydiae in 78% of the flocks.
Significant genes with differential expressions were taken into account for further analysis using the SAM (Significance Analysis of Microarrays) test with an FDR below 5%.
Geng J, Picker J, Zheng Z, Zhang X, Wang J, Hisama F, Brown DW, Mullen MP, Harris D, Stoler J, Seman A, Miller DT, Fu Q, Roberts AE, Shen Y. Chromosome microarray testing for patients with congenital heart defects reveals novel disease causing loci and high diagnostic yield.
The use of microarray testing in individuals with ASD and MCA has significantly increased the rate of identification of an underlying genetic etiology.
Only samples previously tested with the Versant™ HCV assay were available for microarray testing.
Family 9 had chromosome microarray testing, followed by reanalysis of exome data (Ambry Genetics, Santa Clara, CA).
Coulter, M. E. et al. Chromosomal microarray testing influences medical management.
We chose 14 SYNZIPs for in vitro testing, selecting proteins that had many interaction partners in the prior coiled-coil microarray tests or that interacted with a SYNZIP that had many interaction partners.
Furthermore, two negative control samples testing negative with the Versant™ HCV assay, also tested negative with the microarray test.
